ASCO 2023 | Final analysis of distant metastasis-free survival in the KEYNOTE-716 study

So here at ASCO 2023, we present the final distant metastasis free survival analysis per protocol specification. And what we see now is that with longer follow up, the benefit in terms of DMFS maintains statistical significance and in fact increases in terms of clinical magnitude. And what I mean by that is with further follow up, it’s becoming more and more clear that pembrolizumab has a major impact on DMFS to the tune now, at 36 months, the hazard ratio at 0.5, 9 or 41% improvement in the recurrent in distant metastasis free survival. And I think that’s quite meaningful to really emphasize the point that these patients with stage two disease are at high risk and do benefit from pembrolizumab.